Conclusion
pancreatic cancer, disulfidptosis
PANCREATIC CANCER
In this study, we applied the subtyping model of disulfidptosis to pancreatic cancer for the first time and constructed a risk signature based on the disulfidptosis subtype, which can provide an accurate assessment of prognosis, immunotherapy, and chemotherapy response in PCa patients, opening up new targets and directions for the prognosis and treatment of pancreatic cancer.